PTEN, PIK3CA, p-AKT, and p-p70S6K status: Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer

Francisco J. Esteva, Hua Guo, Siyuan Zhang, Cesar Santa-Maria, Steven Stone, Jerry S. Lanchbury, Aysegul A. Sahin, Gabriel N. Hortobagyi, Dihua Yu

Research output: Contribution to journalArticle

Abstract

Phosphatase and tensin homolog (PTEN) is a key modulator of trastuzumab sensitivity in HER2-overexpressing breast cancer. Because PTEN opposes the downstream signaling of phosphoinositide 3-kinase (PI3K), we investigated the role of PTEN and other components of the PI3K pathway in trastuzumab resistance. We analyzed the status of PTEN, p-AKT-Ser473, and p-p70S6K-Thr389 using immunohistochemistry. PIK3CA mutation status was analyzed by direct sequencing. Primary tumor tissue was available from 137 patients with HER2-overexpressing metastatic breast cancer who had received trastuzumab-based chemotherapy. We observed that each of the four biomarkers alone did not significantly correlate with trastuzumab response, whereas PTEN loss alone significantly correlated with shorter survival times (P = 0.023). PI3K pathway activation, defined as PTEN loss and/or PIK3CA mutation, was associated with a poor response to trastuzumab (P = 0.047) and a shorter survival time (P = 0.015). PTEN loss was significantly associated with a poor response to trastuzumab (P = 0.028) and shorter survival time (P = 0.008) in patients who had received first-line trastuzumab and in patients with estrogen receptor- (P = 0.029) and progesterone receptor-negative tumors (P = 0.033). p-AKT-Ser473 and p-p70S6K-Thr389 each had a limited correlation with trastuzumab response. When these markers were combined with PTEN loss, an increased correlation with patient outcome was observed. In conclusion, PI3K pathway activation plays a pivotal role in trastuzumab resistance. Our findings may facilitate the evaluation of tumor response to trastuzumab-based and targeted therapies.

Original languageEnglish (US)
Pages (from-to)1647-1656
Number of pages10
JournalAmerican Journal of Pathology
Volume177
Issue number4
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

70-kDa Ribosomal Protein S6 Kinases
Phosphoric Monoester Hydrolases
Breast Neoplasms
Survival
1-Phosphatidylinositol 4-Kinase
Trastuzumab
Tensins
Neoplasms
Mutation
Progesterone Receptors
Estrogen Receptors
Biomarkers
Immunohistochemistry

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

PTEN, PIK3CA, p-AKT, and p-p70S6K status : Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. / Esteva, Francisco J.; Guo, Hua; Zhang, Siyuan; Santa-Maria, Cesar; Stone, Steven; Lanchbury, Jerry S.; Sahin, Aysegul A.; Hortobagyi, Gabriel N.; Yu, Dihua.

In: American Journal of Pathology, Vol. 177, No. 4, 01.01.2010, p. 1647-1656.

Research output: Contribution to journalArticle

Esteva, Francisco J. ; Guo, Hua ; Zhang, Siyuan ; Santa-Maria, Cesar ; Stone, Steven ; Lanchbury, Jerry S. ; Sahin, Aysegul A. ; Hortobagyi, Gabriel N. ; Yu, Dihua. / PTEN, PIK3CA, p-AKT, and p-p70S6K status : Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. In: American Journal of Pathology. 2010 ; Vol. 177, No. 4. pp. 1647-1656.
@article{d8c6bec5dbca493582400e72c7d87133,
title = "PTEN, PIK3CA, p-AKT, and p-p70S6K status: Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer",
abstract = "Phosphatase and tensin homolog (PTEN) is a key modulator of trastuzumab sensitivity in HER2-overexpressing breast cancer. Because PTEN opposes the downstream signaling of phosphoinositide 3-kinase (PI3K), we investigated the role of PTEN and other components of the PI3K pathway in trastuzumab resistance. We analyzed the status of PTEN, p-AKT-Ser473, and p-p70S6K-Thr389 using immunohistochemistry. PIK3CA mutation status was analyzed by direct sequencing. Primary tumor tissue was available from 137 patients with HER2-overexpressing metastatic breast cancer who had received trastuzumab-based chemotherapy. We observed that each of the four biomarkers alone did not significantly correlate with trastuzumab response, whereas PTEN loss alone significantly correlated with shorter survival times (P = 0.023). PI3K pathway activation, defined as PTEN loss and/or PIK3CA mutation, was associated with a poor response to trastuzumab (P = 0.047) and a shorter survival time (P = 0.015). PTEN loss was significantly associated with a poor response to trastuzumab (P = 0.028) and shorter survival time (P = 0.008) in patients who had received first-line trastuzumab and in patients with estrogen receptor- (P = 0.029) and progesterone receptor-negative tumors (P = 0.033). p-AKT-Ser473 and p-p70S6K-Thr389 each had a limited correlation with trastuzumab response. When these markers were combined with PTEN loss, an increased correlation with patient outcome was observed. In conclusion, PI3K pathway activation plays a pivotal role in trastuzumab resistance. Our findings may facilitate the evaluation of tumor response to trastuzumab-based and targeted therapies.",
author = "Esteva, {Francisco J.} and Hua Guo and Siyuan Zhang and Cesar Santa-Maria and Steven Stone and Lanchbury, {Jerry S.} and Sahin, {Aysegul A.} and Hortobagyi, {Gabriel N.} and Dihua Yu",
year = "2010",
month = "1",
day = "1",
doi = "10.2353/ajpath.2010.090885",
language = "English (US)",
volume = "177",
pages = "1647--1656",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - PTEN, PIK3CA, p-AKT, and p-p70S6K status

T2 - Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer

AU - Esteva, Francisco J.

AU - Guo, Hua

AU - Zhang, Siyuan

AU - Santa-Maria, Cesar

AU - Stone, Steven

AU - Lanchbury, Jerry S.

AU - Sahin, Aysegul A.

AU - Hortobagyi, Gabriel N.

AU - Yu, Dihua

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Phosphatase and tensin homolog (PTEN) is a key modulator of trastuzumab sensitivity in HER2-overexpressing breast cancer. Because PTEN opposes the downstream signaling of phosphoinositide 3-kinase (PI3K), we investigated the role of PTEN and other components of the PI3K pathway in trastuzumab resistance. We analyzed the status of PTEN, p-AKT-Ser473, and p-p70S6K-Thr389 using immunohistochemistry. PIK3CA mutation status was analyzed by direct sequencing. Primary tumor tissue was available from 137 patients with HER2-overexpressing metastatic breast cancer who had received trastuzumab-based chemotherapy. We observed that each of the four biomarkers alone did not significantly correlate with trastuzumab response, whereas PTEN loss alone significantly correlated with shorter survival times (P = 0.023). PI3K pathway activation, defined as PTEN loss and/or PIK3CA mutation, was associated with a poor response to trastuzumab (P = 0.047) and a shorter survival time (P = 0.015). PTEN loss was significantly associated with a poor response to trastuzumab (P = 0.028) and shorter survival time (P = 0.008) in patients who had received first-line trastuzumab and in patients with estrogen receptor- (P = 0.029) and progesterone receptor-negative tumors (P = 0.033). p-AKT-Ser473 and p-p70S6K-Thr389 each had a limited correlation with trastuzumab response. When these markers were combined with PTEN loss, an increased correlation with patient outcome was observed. In conclusion, PI3K pathway activation plays a pivotal role in trastuzumab resistance. Our findings may facilitate the evaluation of tumor response to trastuzumab-based and targeted therapies.

AB - Phosphatase and tensin homolog (PTEN) is a key modulator of trastuzumab sensitivity in HER2-overexpressing breast cancer. Because PTEN opposes the downstream signaling of phosphoinositide 3-kinase (PI3K), we investigated the role of PTEN and other components of the PI3K pathway in trastuzumab resistance. We analyzed the status of PTEN, p-AKT-Ser473, and p-p70S6K-Thr389 using immunohistochemistry. PIK3CA mutation status was analyzed by direct sequencing. Primary tumor tissue was available from 137 patients with HER2-overexpressing metastatic breast cancer who had received trastuzumab-based chemotherapy. We observed that each of the four biomarkers alone did not significantly correlate with trastuzumab response, whereas PTEN loss alone significantly correlated with shorter survival times (P = 0.023). PI3K pathway activation, defined as PTEN loss and/or PIK3CA mutation, was associated with a poor response to trastuzumab (P = 0.047) and a shorter survival time (P = 0.015). PTEN loss was significantly associated with a poor response to trastuzumab (P = 0.028) and shorter survival time (P = 0.008) in patients who had received first-line trastuzumab and in patients with estrogen receptor- (P = 0.029) and progesterone receptor-negative tumors (P = 0.033). p-AKT-Ser473 and p-p70S6K-Thr389 each had a limited correlation with trastuzumab response. When these markers were combined with PTEN loss, an increased correlation with patient outcome was observed. In conclusion, PI3K pathway activation plays a pivotal role in trastuzumab resistance. Our findings may facilitate the evaluation of tumor response to trastuzumab-based and targeted therapies.

UR - http://www.scopus.com/inward/record.url?scp=77957352037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957352037&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2010.090885

DO - 10.2353/ajpath.2010.090885

M3 - Article

C2 - 20813970

AN - SCOPUS:77957352037

VL - 177

SP - 1647

EP - 1656

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 4

ER -